China & US based Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and...
Teva Hong Kong has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network (KLN)....
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has successfu...
WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialisi...
A newly released white paper, based on research conducted independently by IQVIA, a global healthcare consultancy, ...
US-based biotech firm Indaptus Therapeutics, Inc. has secured new patent approvals in China, Japan and Israel for its De...
Amid intensifying U.S.-China trade tensions, Beijing has escalated its retaliatory measures by banning U.S. biot...
Boehringer Ingelheim’s biopharmaceutical facility in Shanghai, China, meets the conditions to participate in a reg...
China-based WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has...
WuXi Biologics, a leading global contract research, development, and manufacturing organization (CRDMO...
Japan-headquartered pharmaceutical firm Eisai has entered into an exclusive license agreement with a subsidiary of SciCl...
GE HealthCare (GEHC), a leading global healthcare solutions provider, has announced that Yihao Zhang, president and Chie...
ZEISS Medical Technology has announced that the National Medical Products Administration (NMPA) in China has a...
Florricks Lifecare, a leading research-driven pharmaceutical company in India, involved in R&D, production, and sale...
US-based startup HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by China-based Harb...
China-based WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization...
The Hong Kong Polytechnic University (PolyU) and Peking University Health Science Center (Peking University) signed a Me...
FibroGen, Inc. has announced the sale of its China subsidiary to AstraZeneca for approximately $160 million. Under the t...
